HS resource center

Therapies for hidradenitis suppurativaAlthough hidradenitis suppurativa is a disease that is extremely impactful and burdensome several medical therapies have been proven to be effective and safe.
Combined therapy targets inflammationResearchers treated a small cohort with two anti-inflammatory drugs and saw a significant improvement in clinical manifestations of disease. Further data showed the approach safely maintained results.
HS treatment requires multipronged approach
HS treatment requires multipronged approachEvidence supports combined treatments to target the many factors tied to hidradenitis suppurativa. See one expert's recommendations.
Hidradenitis suppurativa misunderstood and underdiagnosedMisconceptions about hidradenitis suppurativa (HS) prevent dermatologists and other clinicians from properly diagnosing and treating what one expert says is a “crippling disease.”
Hidradenitis Suppurativa therapy options progressing
Hidradenitis Suppurativa therapy options progressingMany physicians miss diagnosing hidradenitis suppurativa upon first presentation. Recognizing key traits may help physicians diagnose and begin treatment of the disease earlier.
TNF Inhibitors Prove EffectiveTNF inhibitors shown to be effective in improving the clinical symptoms of moderate to severe hidradenitis suppurativa, representing an exciting therapeutic option for this challenging disease.
Infection-causing bacteria found in hidradenitis suppurativa lesionsBacteria responsible for causing skin and soft tissue infections has been found in hidradenitis suppurativa lesions, results of a recent study indicate.
Early results encouraging in study of adalimumab for hidradenitis suppurativaNew results from a phase-3 study demonstrating the effect of Humira (adalimumab, AbbVie) in treating moderate-to-severe hidradenitis suppurativa (HS) may lead to worldwide regulatory filings for expanded use of the drug.
Algorithm provides quicker diagnosis of hidradenitis suppurativaHidradenitis suppurativa (HS) is a challenging disease to treat; however, a better understanding of the disease and continued research has led to more clear-cut therapeutic options, according to an expert who spoke at the North American Clinical Dermatologic Society meeting.
Clinicians emphasize risk of skin cancer in patients with skin of colorThere is a misconception that people with skin of color are not at risk of skin cancer, and dermatologists are responsible for better educating themselves and their patients about this danger, says an expert who spoke at the 72nd Annual Meeting of the American Academy of Dermatology.